Bladder Cancer Advocacy Network Discusses Why Bladder Cancer Demands Attention Now with YourUpdateTV

Bladder cancer is one of the most common, and most overlooked, cancers in the United States, impacting hundreds of thousands of families each year. This is a public health issue that touches families, ...
Fierce Pharma

Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) ...
Flow Space on MSN

Hysterectomy: Here's how the common procedure impacts long-term health

The common procedure can impact your health in surprising ways.

Natera Gets FDA Approval for Bladder-Cancer Test

Natera said the Food and Drug Administration approved its Signatera CDx as a test for bladder cancer. The drug can be used as a companion diagnostic with adjuvant atezolizumab to treat muscle-invasive ...

Verathon Expands Urology Portfolio with CFlex™, Its First Single-Use Flexible Cystoscope

Designed to simplify setup, improve visualization, and expand maneuverability in cystoscopy procedures. BOTHELL, WA, ...
360Dx

Valar Labs Bladder Cancer Prognostic Nabs FDA Breakthrough Device Designation

The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.